Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa

Journal of Medical Virology

Volumn 81, Issue 11, 2009, Pages 1860-1868

  Compston, Lara Isobel ^a   Li, Chengyao ^b   Sarkodie, Francis ^c   Owusu Ofori, Shirley ^c   Opare Sem, Ohene ^c   Allain, Jean Pierre ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

Author keywords

GB virus C (GBV C); Hepatitis B Virus (HBV); Herpesviruses; HIV; Immunodeficiency; Occult hepatitis B infection; Parvovirus B19V; Sub Saharan Africa

Indexed keywords

IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AFRICA; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PARVOVIRUS; POLYMERASE CHAIN REACTION; PREVALENCE; SEROPREVALENCE; VARICELLA ZOSTER VIRUS; VIREMIA;

ADOLESCENT; BLOOD CELLS; COMORBIDITY; CYTOMEGALOVIRUS; GB VIRUS C; GHANA; HEPATITIS B VIRUS; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PARVOVIRUS B19, HUMAN; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; VIREMIA; VIRUS DISEASES; VIRUS LATENCY; YOUNG ADULT;

CYTOMEGALOVIRUS; GB VIRUS C; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 3; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; PARVOVIRUS;

EID: 70350445723     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21614     Document Type: Article

References (50)

1. Albrecht D, Meyer T, Lorenzen T, Stoehr A, Arndt R, Plettenberg A. 2004. Epidemiology of HHV-8 infection in HIV-positive patients with and without Kaposi sarcoma: Diagnostic relevance of serology and PCR. J Clin Virol 30:145-149. (Pubitemid 38582021)
2. Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, Shyamala V, Yeboah F, Anokwa M, Owusu-Ofori S, Opare-Sem O. 2003. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 101:2419-2425. (Pubitemid 36302091)
3. Bonnet F, Jouvencel AC, Parrens M, Leon MJ, Cotto E, Garrigue I, Morlat P, Beylot J, Fleury H, Lafon ME. 2006. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 36:258-263. (Pubitemid 44066893)
4. Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, Mphahlele MJ. 2005. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: A call for further investigation. Liver Int 25:201-213. (Pubitemid 40500550)
5. Chamorro AJ, Casado JL, Bellido D, Moreno S. 2005. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 24:492-494. (Pubitemid 41124504)
6. Chang Y, Moore PS. 1996. Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. Infect Agents Dis 5:215-222. (Pubitemid 26317984)
7. Collenberg E, Ouedraogo T, Ganame J, Fickenscher H, Kynast-Wolf G, Becher H, Kouyate B, Krausslich HG, Sangare L, Tebit DM. 2006. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. J Med Virol 78:683-692.
8. Compston LI, Sarkodie F, Candotti D, Opare-Sem O, Allain JP. 2008. Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions. J Virol Methods 151:47-54.
9. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. 1991. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 4:770-776.
10. de Ona M, Melon S, Galarraga MC, Palacio A, Lambert JL, Bernardo MJ, Rodriguez M, Gomez E. 2005. Comparison of cytomegalovirus pp-65 antigenemia assay and plasma DNA correlation with the clinical outcome in transplant recipients. Transpl Int 18:43-46. (Pubitemid 41742944)
11. de Souza VA, Pierrotti LC, Sumita LM, Freire WS, Segurado AA, Pannuti CS. 2007. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count. J Med Virol 79:1562-1568.
12. Dehee A, Asselot C, Piolot T, Jacomet C, Rozenbaum W, Vidaud M, Garbarg-Chenon A, Nicolas JC. 2001. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 65:543-552. (Pubitemid 32959083)
13. Douek DC, Picker LJ, Koup RA. 2003. T cell dynamics in HIV-1 infection. Annu Rev Immunol 21:265-304.
14. Eis-Hubinger AM, Reber U, Abdul-Nour T, Glatzel U, Lauschke H, Putz U. 2001. Evidence for persistence of parvovirus B19 DNA in livers of adults. J Med Virol 65:395-401.
15. Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, Elmore S, Moore DT, Schichman SA, Swinnen LJ, Gulley ML. 2005. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 75:59-69. (Pubitemid 39578791)
16. Fattovich G, Bortolotti F, Donato F. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 48:335-352.
17. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, Sagnelli C, De Stefano G, Ferraro T, De Stefano C, Sagnelli E. 2006. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20:1253-1260. (Pubitemid 44030373)
18. Gartner BC, Schafer H, Marggraff K, Eisele G, Schafer M, Dilloo D, Roemer K, Laws HJ, Sester M, Sester U, Einsele H, Mueller-Lantzsch N. 2002. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 40:351-358. (Pubitemid 34130852)
19. Goedert JJ, Vitale F, Lauria C, Serraino D, TamburiniM, Montella M, Messina A, Brown EE, Rezza G, Gafa L, Romano N. 2002. Risk factors for classical Kaposi's sarcoma. J Natl Cancer Inst 94:1712-1718. (Pubitemid 35446840)
20. Hadlock KG, Foung SK. 1998. GBV-C/HGV: A new virus within the Flaviviridae and its clinical implications. Transfus Med Rev 12:94-108.
21. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. 2002. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol 40:933-936. (Pubitemid 34208648)
22. Hu KQ. 2002. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9:243-257. (Pubitemid 36002459)
23. Jabs WJ, Hennig H, Kittel M, Pethig K, Smets F, Bucsky P, Kirchner H, Wagner HJ. 2001. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 39:564-569. (Pubitemid 32150818)
24. Jain M, Chakravarti A, Verma V, Bhalla P. 2009. Seroprevalence of hepatitis viruses in patients infected with the human immunodeficiency virus. Indian J Pathol Microbiol 52:17-19.
25. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic O. 2005. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 6:140-143. (Pubitemid 40425979)
26. Karayiannis P, Pickering J, Zampino R, Thomas HC. 1998. Natural history and molecular biology of hepatitis G virus/GB virus C. Clin Diagn Virol 10:103-111. (Pubitemid 28399028)
27. Lucas KG, Filo F, Heilman DK, Lee CH, Emanuel DJ. 1998. Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Blood 92:3977-3978. (Pubitemid 28525226)
28. Maidana MT, Sabino EC, Kallas EG. 2005. GBV-C/HGV and HIV-1 coinfection. Braz J Infect Dis 9:122-125.
29. Malope BI, MacPhail P, Mbisa G, MacPhail C, Stein L, Ratshikhopha EM, Ndhlovu L, Sitas F, Whitby D. 2008. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS (London, England) 22:519-526. (Pubitemid 351317294)
30. Manzardo C, Zaccarelli M, Aguero F, Antinori A, Miro JM. 2007. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 46:S9-S18. (Pubitemid 47312321)
31. Marshall BC, Jacobson MA, Adler SP. 2004. Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. Viral Immunol 17:101-108.
32. Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debre P, Rouzioux C, Autran B. 2005. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 191:2053-2063.
33. Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. 1998. Risk factors for horizontal transmission of hepatitis B virus in a rural district in Ghana. Am J Epidemiol 147:478-487. (Pubitemid 28146108)
34. McDade TW, Stallings JF, Angold A, Costello EJ, Burleson M, Cacioppo JT, Glaser R, Worthman CM. 2000. Epstein-Barr virus antibodies in whole blood spots: Aminimally invasive method for assessing an aspect of cell-mediated immunity. Psychosom Med 62:560-567. (Pubitemid 30604801)
35. Mindel A, Tenant-Flowers M. 2001. ABC of AIDS: Natural history and management of early HIV infection. Br Med J (Clin Res Ed) 322:1290-1293. (Pubitemid 32493966)
36. Moriuchi M, Moriuchi H. 2003. Increased susceptibility to HIV-1 of peripheral blood lymphocytes in acute infection with Epstein-Barr virus. J Med Virol 71:343-346. (Pubitemid 37176622)
37. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM. 2007. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79:1464-1471. (Pubitemid 47328734)
38. Newton R, Carpenter L, Casabonne D, Beral V, Babiker A, Darbyshire J, Weller I, Weiss R, Kwan A, Bourboulia D, Munoz F, Lagos D, Boshoff C. 2006. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. Br J Cancer 94:1504-1509. (Pubitemid 43772288)
39. Parsyan A, Kerr S, Owusu-Ofori S, Elliott G, Allain JP. 2006. Reactivity of genotype-specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic. J Clin Microbiol 44:1367-1375.
40. Plancoulaine S, Abel L, van Beveren M, Tregouet DA, Joubert M, Tortevoye P, de The G, Gessain A. 2000. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 356:1062-1065. (Pubitemid 30743293)
41. Powderly WG. 1999. The interaction of opportunistic infections and HIV replication. AIDS 13:1603-1606. (Pubitemid 30015705)
42. Preiksaitis JK, Brennan DC, Fishman J, Allen U. 2005. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5:218-227. (Pubitemid 40179508)
43. Schattner A, Hanuka N, Sarov B, Sarov I, Handzel Z, Bentwich Z. 1991. Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion. Clin Exp Immunol 85:209-213.
44. Soria A, Lazzarin A. 2007. Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease. J Acquir Immune Defic Syndr 46:S19-S30. (Pubitemid 47315643)
45. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ. 1999. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 73:7027-7030. (Pubitemid 29327888)
46. Suligoi B, Dorrucci M, Uccella I, Andreoni M, Rezza G. 2003. Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. J Med Virol 69:182-187. (Pubitemid 36068872)
47. Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ. 2004. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol 113:742-746. (Pubitemid 38530432)
48. Van Baarle D, Wolthers KC, Hovenkamp E, Niesters HG, Osterhaus AD, Miedema F, Van Oers MH. 2002. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 186:405-409. (Pubitemid 34816324)
49. Veenstra J, van Praag RM, Krol A, Wertheim van Dillen PM, Weigel HM, Schellekens PT, Lange JM, Coutinho RA, van der Meer JT. 1996. Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS 10:393-399. (Pubitemid 26117310)
50. World Health Organisation. 2006. WHO case definitions of HIV surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: WHO. pp 1-40.